Togaviridae Or Flaviviridae, Except Hepatitis C Virus (e.g., Yellow Fever Virus, Bovine Viral Diarrhea Virus, Dengue Virus, Equine Viral Arteritis Virus, Equine Encephalitis Virus, Japanese B Encephalitis Virus, Sindbis Virus, Flavivirus, Etc.) Patents (Class 424/218.1)
  • Patent number: 10881723
    Abstract: The present invention relates to a vaccine containing fixed virus particles, wherein a summed fever response of three rabbits to the fixed virus particles in a pyrogen test is less than 80% based on a summed fever response of three rabbits to original virus particles of the fixed virus particles or corresponding inactivated virus particles.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: January 5, 2021
    Assignee: KM BIOLOGICS CO., LTD.
    Inventors: Hiroto Onuma, Yukari Tsurudome, Kazuyuki Ikeda, Ryo Yamaue, Kazuhiko Kimachi, Motoharu Abe, Akihiro Watanabe, Yuki Ohara
  • Patent number: 10869920
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: December 22, 2020
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, The Government of the United States, as represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Patent number: 10588956
    Abstract: The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: March 17, 2020
    Assignee: Bharat Biotech International Limited
    Inventors: Kandaswamy Sumathy, Krishna Murthy Ella
  • Patent number: 10533997
    Abstract: Embodiments of the invention are directed to stable full-length cDNA clones of a clinical, Asian lineage ZIKV strain. Certain embodiments of the invention are directed to high-throughput assays for ZIKV and dengue virus (DENV) diagnosis.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: January 14, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Pei-Yong Shi, Chao Shan, Xuping Xie
  • Patent number: 10463741
    Abstract: The present invention provides a composition for use as the protectant for a live attenuated influenza virus vaccine, comprising the following components at the following concentrations: human serum albumin: 1.0-15.0 g/L, sugar: 15.0-95.0 g/L, and sodium glutamate: 0.5-15.0 g/L. The present invention also provides a process for preparing a live attenuated influenza vaccine with the composition according to the present invention, comprising the following steps: dissolving the components of the composition according to the present invention sequentially into a pH buffer solution, adjusting the pH to a specified value, performing filtration sterilization, and adding virus stock to give the live attenuated influenza vaccine. The present invention further provides a live attenuated influenza vaccine, which may be used as an injection or nasal spray.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: November 5, 2019
    Assignee: Changchun BCHT Biotechnology Co.
    Inventors: Zhenwei Shen, Xiaohui Chen, Fei Xu, Yao Sun, Xiaogeng Cheng, Changlin Zhu, Chunlai Jiang, Wei Kong
  • Patent number: 10369209
    Abstract: A group of mosquito-borne flaviviruses that cause fatal encephalitis in humans is among the most important of all emerging human pathogens of global significance. This group includes Japanese encephalitis virus (JEV), West Nile virus, St. Louis encephalitis virus, and Murray Valley encephalitis virus. In the present disclosure, the first reverse genetics system has been developed for SA14-14-2, a live JE vaccine that is most commonly used in most JE-endemic areas, by constructing an infectious bacterial artificial chromosome that contains the full-length SA14-14-2 cDNA. Using this infectious SA 14-14-2 cDNA, combined with a mouse model for JEV infection, a key viral neurovirulence factor has been discovered that is a conserved single amino acid in the ij hairpin adjacent to the fusion loop of the viral E glycoprotein, which regulates viral infectivity into neurons within the central nervous system.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: August 6, 2019
    Assignee: Utah State University
    Inventor: Young-Min Lee
  • Patent number: 10357553
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: July 23, 2019
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Patent number: 10357558
    Abstract: The present invention relates to a method for inducing an immune response to the dengue virus, on the basis of DNA and 17D chimeric virus vaccines in combined or co-administered immunisation. The scope of the present invention also includes DNA vaccines against the four serotypes of the dengue virus, produced by forming, from each viral serotype of the dengue virus (DENV1-4), various recombinant plasmids that contain the gene that codes for the E protein, or that contain only the sequence that corresponds to the domain III of this protein. The invention also provides a vaccine composition consisting of (a) DNA vaccines against the four serotypes of the dengue virus; (b) chimeric viruses comprising the modified yellow fever vaccination virus 17D; and (c) a pharmaceutically acceptable carrier, all of which are covered by the scope of the invention.
    Type: Grant
    Filed: August 1, 2010
    Date of Patent: July 23, 2019
    Assignee: Fundacao Oswaldo Cruz
    Inventors: Ada Maria de Barcelos Alves, Adriana de Souza Azevedo, Ricardo Galler, Marcos da Silva Freire
  • Patent number: 10351597
    Abstract: A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPAR?, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-?1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: July 16, 2019
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10293038
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: May 21, 2019
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Patent number: 10238734
    Abstract: The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immunostimulatory intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracelluar signaling peptide must be present in a complex of three or more units in order to stimulate an immune response. Inserting this fusion construct into viruses like HIV-1 or introducing it into dendritic cells or tumor cells is predicted to lead to a positive therapeutic effect in humans, non-human mammals, birds, and fish.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: March 26, 2019
    Assignee: The Regents of the University of California
    Inventors: Richard Syd Kornbluth, Geoffrey William Stone
  • Patent number: 10201602
    Abstract: A live or inactivated recombinant vaccine is described, comprising a viral vector and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, wherein the viral vector is capable of generating a cell immune response due to an increased alpha and/or gamma interferon production, and is capable of a quick replication, and it has inserted a nucleotide sequence of the ORF 5 and ORF 6 from PRSS.
    Type: Grant
    Filed: May 7, 2011
    Date of Patent: February 12, 2019
    Assignee: LABORATORIO AVI-MEX, S.A. DE C.V.
    Inventors: Bernardo Lozano-Dubernard, Ernesto Soto-Priante, David Sarfati-Mizrahi, Jesús Horacio Lara-Puente
  • Patent number: 10159727
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: December 25, 2018
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Patent number: 10143741
    Abstract: The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: December 4, 2018
    Assignee: Sanofi Pasteur SA
    Inventors: Alain Bouckenooghe, Remi Forrat, Denis Crevat
  • Patent number: 10081795
    Abstract: Methods and compositions concerning mutant flaviviruses with host range mutations. In some embodiments the invention concerns nucleotide sequences that encode mutant flavivirus proteins. Viruses comprising these sequences that display reduced replication in mammalian cells are provided. In further aspects of the invention, flavivirus vaccine compositions are provided. In another embodiment the invention provides methods for vaccination against flavivirus infection.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: September 25, 2018
    Assignees: Research Development Foundation, Arbovax, Inc.
    Inventors: Dennis T. Brown, Raquel Hernandez, Malcolm E. Thomas, Katherine M. Smith
  • Patent number: 10058602
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: August 28, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, The Walter Reed Army Institute of Research
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Patent number: 10004795
    Abstract: The present invention refers to a process for preparing an attenuated tetravalent dengue vaccine and its product. The present invention also refers to a process for preparing a tetravalent dengue vaccine for administration to a subject, to a method for inducing an immune response to virus dengue serotype 1, 2, 3 and 4 in a patient and to a tetravalent dengue vaccine kit.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: June 26, 2018
    Assignee: Fundacao Butantan
    Inventor: Neuza Maria Frazatti Gallina
  • Patent number: 9993544
    Abstract: The present invention relates i.a. to a CSFV (classical swine fever virus) comprising a substitution of proline to lysine at amino acid position 44 of the E2 protein and a substitution of threonine to aspartic acid at amino acid position 45 of the E2 protein. Further, the present invention provides an immunogenic composition comprising the CSFV of the present invention and the use of the immunogenic composition for reducing the incidence of or severity in an animal of one or more clinical signs associated with CSF. Moreover, the present invention provides a method of differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: June 12, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Gregor Meyers, Sabine Wirtz
  • Patent number: 9962435
    Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: May 8, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Kristina J. Hennessy, Phillip Wayne Hayes
  • Patent number: 9944902
    Abstract: The present invention describes an efficient commercial scale production method for the preparation of PRRS virus.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: April 17, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Elizabeth Jane Berry, Fuad Tawfiq Haddadin, Ali Khazraeinazmpour, Jeremy Kroll, Sonia Regina Cantisano Malburg, Edgar Arnulfo Sandoval Basurto, Stephen Scheerer
  • Patent number: 9861692
    Abstract: The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine is a live, attenuated dengue vaccine and the second dengue vaccine is a recombinant dengue subunit vaccine or an inactivated dengue vaccine; wherein the live attenuated dengue vaccine comprises at least one live, attenuated dengue virus or at least one live attenuated chimeric flavivirus. The dengue virus vaccine compositions of the invention may further comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent. The invention also relates to methods of using the dengue virus vaccine compositions of the invention to treat or prevent dengue infection, or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: January 9, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew Bett, Beth-Ann Griswold Coller, Govindarajan Dhanasekaran, Ramesh V. Chintala
  • Patent number: 9827303
    Abstract: The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to the biopharmaceutical agent, at least an amino acid, a polyol and a metal salt. Preferably the amino acid is glutamate, the polyol is sorbitol and optionally also mannitol and the metal salt is a magnesium salt. The solution is dried by vacuum drying or by lyophilization. The methods are particularly useful for preparing dried formulations of viruses such as poliovirus or respiratory syncytial virus to be used for vaccination. The invention also relates to dried formulations prepared in accordance with the methods of the invention and to their use as medicaments, e.g. as vaccines.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: November 28, 2017
    Assignee: De Staat der Nederlanden, vert. door de minister van VWS, Ministerie van Volksgezondheid, Welzijn en Sport
    Inventors: Heleen Kraan, Jean-Pierre Amorij
  • Patent number: 9790473
    Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: October 17, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
  • Patent number: 9730997
    Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: August 15, 2017
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
  • Patent number: 9719994
    Abstract: The invention relates to a method of in-vitro detection of an infection with a hepatitis C virus (HCV) in a biological sample, comprising the simultaneous detection of the HCV capsid protein and of an antibody directed against said capsid protein, said method using, for capturing the anti-capsid antibodies, a peptide comprising an antigenic fragment derived from the truncated HCV capsid. The invention also relates to the peptide for capturing the anti-capsid antibodies and the kits comprising it.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: August 1, 2017
    Assignee: BIO-RAD INNOVATIONS
    Inventors: Stephane Gadelle, Francois Rieunier
  • Patent number: 9701719
    Abstract: Novel attenuating deletions of Chikungunya virus E2 polypeptides are provided as are attenuated viruses comprising the deletions. Also provided are immunogenic compositions comprising the attenuated viruses and methods of producing such viruses in cells (such as insect cells). Viruses of the embodiments can be used for immunization of animals to provide protection from the pathogenic effects of Chikungunya virus infection.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: July 11, 2017
    Assignee: Research Development Foundation
    Inventors: Dennis T. Brown, Raquel Hernandez
  • Patent number: 9683244
    Abstract: Embodiments are directed compositions related to Eilat virus and uses thereof.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: June 20, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Scott C. Weaver, Farooq Nasar, Rodion V. Gorchakov, Hilda Guzman, Naomi Forrester, Gustavo Palacios, Ian W. Lipkin, Robert B. Tesh
  • Patent number: 9655961
    Abstract: The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 23, 2017
    Assignees: INSTITUT PASTEUR, THEMIS BIOSCIENCE GMBH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic Tangy, Samantha Brandler, Philippe Despres, Andre Habel
  • Patent number: 9642908
    Abstract: Disclosed is an in vivo equine disease model and a method of preparing the disease model for equine herpesvirus-1 neurological disease comprising a horse having a low pre-exposure level of herpesvirus-specific CTL precursors wherein the horse is experimentally infected with a neuropathogenic strain of equine herpesvirus or a mutant thereof. Also disclosed is a method of quantifying the risk factors and predicting the development of clinical neurologic signs of equine herpesvirus-1 neurological disease in a horse. Also described in the invention is the determination of the risk of developing the clinical neurologic signs by a mathematical equation. A new live, attenuated vaccine formulation is disclosed that is effective against neurologic disease due to equine herpesvirus-1.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: May 9, 2017
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: George P. Allen, Glenda Ross
  • Patent number: 9637521
    Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: May 2, 2017
    Assignee: Emergex Vaccines Holdings Limited
    Inventor: Ramila Philip
  • Patent number: 9517259
    Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: December 13, 2016
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Kristina J. Hennessy, Phillip Wayne Hayes
  • Patent number: 9499588
    Abstract: This invention provides flavivirus vaccines that comprise live-attenuated flaviviruses and methods of making and using these vaccines. The flavivirus vaccines described herein possess higher potency due to in situ production of additional immunogens in a way that mimics viral infection and the vaccines have potential for higher potency, reducing costs for production and delivery.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: November 22, 2016
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Peter W. Mason, Tomohiro Ishikawa
  • Patent number: 9442114
    Abstract: The present invention concerns wild-strains of Chikungunya virus isolated from patients exhibiting severe forms of infection and stemming from a human arbovirosis epidemy. The present invention also concerns polypeptide sequences and fragment thereof derived from their genome, the polynucleotide encoding same and their use as diagnostic products, as vaccine and/or as immunogenic compositions.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: September 13, 2016
    Assignee: INSTITUT PASTEUR
    Inventors: Philippe Despres, Anne-Claire Brehin, Valerie Marechal, Pierre Charneau, Philippe Souque
  • Patent number: 9422529
    Abstract: Embodiments are directed compositions related to Eilat virus and uses thereof. Certain aspects are directed to the detection of non-Eilat entities using a chimeric Eilat alphavirus as a capture agent.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: August 23, 2016
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Farooq Nasar, Jesse Erasmus, Scott C. Weaver
  • Patent number: 9265821
    Abstract: The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: February 23, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Benoit Baras, Dirk Gheysen, Isabelle Solange Lucie Knott, Jean-Paul Prieels, Jean-Francois Toussaint
  • Patent number: 9238843
    Abstract: Disclosed are methods and compositions for identifying viral-specific polynucleotide sequences in a biological sample, and particularly in samples of veterinary origin. Also disclosed are oligonucleotide primer pairs, as well as labeled oligonucleotide detection probes useful in detecting the presence of one or more particular species, strains, types, or subtypes of one or more mammalian pathogens of viral origin, as well as systems, diagnostic kits and articles of manufacture comprising virus-specific primers and labeled detection probes, including those useful in identifying viral components of a multivalent vaccine, and quantitating the potency of particular attenuated, live viruses that comprise a livestock vaccine. In certain embodiments, real-time, quantitative PCR methods have been utilized to identify and distinguish between the three known genetic subtypes of bovine viral diarrhea viruses (BVDV-1a, BVDV-1b, and BVDV-2) in a multivalent bovid shipping fever vaccine.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: January 19, 2016
    Assignee: Eli Lilly and Company
    Inventors: Dale Wade Weise, James Robert Harris
  • Patent number: 9228203
    Abstract: This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: January 5, 2016
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Simon Delagrave, Nathan Brown, Harold Kleanthous, Farshad Guirakhoo, Alexander A. Rumyantsev
  • Patent number: 9211323
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: December 15, 2015
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
  • Patent number: 9198964
    Abstract: The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: December 1, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Beth-Ann Griswold Coller, Vidya B. Pai, D. Elliot Parks, Michele Yelmene, Andrew J. Bett, Timothy Martyak
  • Patent number: 9173575
    Abstract: A method for determining haemodynamic performance in a human or animal subject comprises receiving at a processor data representing haemodynamic variables measured from the subject over time. The haemodynamic variables comprise at least two of Systemic Perfusion Pressure (SPP), Systemic Vascular Resistance (SVR), Cardiac Output (CO), Heart Rate (HR) and Stroke Volume (SV). The data are processed to produce a display signal for causing a display device to present a visual mapping relating the haemodynamic variables according to the relationship SPP=CO×SVR and the visual mapping is displayed on a display device. The visual mapping may be corrected Heart Rate (HR) or include a second mapping which facilitates an adjustment to take account of HR.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: November 3, 2015
    Inventor: Stephen Woodford
  • Patent number: 9139618
    Abstract: The present invention relates to Salmonid alphavirus E2-protein expressed in a bacterial expression system, its use in medicine, vaccines comprising such protein, methods for the preparation of such proteins and methods for the preparation of vaccines comprising such proteins.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: September 22, 2015
    Assignee: Intervet Inc.
    Inventor: Stephane Villoing
  • Patent number: 9132184
    Abstract: This invention provides pharmaceutical compositions, such as vaccines, and methods of making and using such compositions.
    Type: Grant
    Filed: November 7, 2007
    Date of Patent: September 15, 2015
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Daniel C. Vellom, James E. Woiszwillo, Paul DeGeorge, Peter Ciarametaro, Amy Woiszwillo, Dara O'Neil, Jennifer Woiszwillo, Cole Woiszwillo
  • Patent number: 9052321
    Abstract: Provided herein is a mammalian cell transformed to contain a plasmid encoding a T7 or SP6 promoter operably linked to one or more HCV genes, a subgenomic replicon from a flavivirus and a cytoplasmic T7 and SP6 RNA amplification system. Also provided herein are isolated replication-competent HCV particles produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the replication-competent HCV particles from the cell culture. Provided herein are isolated HCV structural proteins produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the HCV structural proteins from the cell culture.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: June 9, 2015
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Bertrand Saunier, Miriam Triyatni, Edward A. Berger
  • Patent number: 9005633
    Abstract: A method to prepare inactivate viral vaccine by exposing the virus to a predetermined concentration of an inactivating psoralen, and a preselected intensity of ultraviolet radiation for a time period sufficiently long to render the virus non-infectious but less than that which would result in degradation of its antigenic characteristics.
    Type: Grant
    Filed: July 17, 2010
    Date of Patent: April 14, 2015
    Assignee: The United States of America as Represented by the Secretary of the Navy.
    Inventors: Tadeusz J. Kochel, Ryan C. Maves, Kevin Porter
  • Patent number: 9000141
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: April 7, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill
  • Patent number: 8993744
    Abstract: Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments (such as the E protein ectodomain and DIII domain) fused to the molecular adjuvant P28. The disclosed nucleic acid and polypeptide sequences can be used as vaccines for immunization against dengue virus infection. In some cases, the vaccine includes a virus-like particle containing the universal dengue virus E protein, or fragment thereof, or the vaccine is a DNA molecule encoding the VLP.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: March 31, 2015
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Nikolaos Vasilakis
  • Publication number: 20150079077
    Abstract: The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others).
    Type: Application
    Filed: January 25, 2013
    Publication date: March 19, 2015
    Inventors: Marc J. Kirchmeier, David E. Anderson
  • Patent number: 8968996
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.
    Type: Grant
    Filed: June 10, 2012
    Date of Patent: March 3, 2015
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
  • Patent number: RE46631
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 12, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph E. Blaney, Kathryn A. Hanley, Ching-Juh Lai
  • Patent number: RE46641
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 19, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph E. Blaney, Kathryn A. Hanley, Ching-Juh Lai